Please use this identifier to cite or link to this item:
|Title:||Vasopressin receptor antagonism--a therapeutic option in heart failure and hypertension.|
|Authors:||Burrell, Louise M;Risvanis, John;Johnston, Colin I;Naitoh, M;Balding, Leanne C|
|Affiliation:||Department of Medicine, University of Melbourne, Austin and Repatriation Medical Centre, Heidelberg, Victoria, Australia. firstname.lastname@example.org|
|Citation:||Experimental Physiology; 85 Spec No(): 259S-265S|
|Abstract:||The precise role of vasopressin in the pathophysiology of cardiovascular disease is controversial, but this peptide hormone is important for several reasons. Firstly, circulating concentrations of vasopressin are elevated in heart failure and some forms of hypertension. Secondly, there is evidence that vasopressin is synthesized not only in the hypophysial-pituitary axis but also in peripheral tissues including the heart where it acts as a paracrine hormone. Thirdly, vasopressin has vasoconstrictor, mitogenic, hyperplastic and renal fluid retaining properties which, by analogy with angiotensin II, may have deleterious effects when present in chronic excess. Finally, the availability of orally active non-peptide vasopressin receptor antagonists allows vasopressin receptor antagonism to be considered as a therapeutic option in cardiovascular disease.|
|Internal ID Number:||10795930|
|Subjects:||Antidiuretic Hormone Receptor Antagonists|
Heart Failure.drug therapy.physiopathology
Spiro Compounds.therapeutic use
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.